

Incidence of *ROS1*-Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients

This article was published in the following Dove Press journal:
Lung Cancer: Targets and Therapy

Anurag Mehta¹
Mumtaz Saifi²
Ullas Batra³
M Suryavanshi²
Kush Gupta⁴

¹Laboratory Services, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India; ²Department of Molecular Pathology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India; ³Medical Oncology, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, India; ⁴Catalyst Clinical Services, New Delhi, India

Background: The *ROS1* gene is a member of the “sevenless” subfamily of tyrosine-kinase insulin-receptor genes. *ROS1*-fusion rearrangement causes constitutive downstream signal transduction, with an oncogenic role in non-small-cell lung carcinoma (NSCLC). Fortunately, crizotinib, an ALK1 tyrosine-kinase inhibitor, provides long-term disease control. The objective of this molecular epidemiological study was to estimate the frequency of *ROS1* rearrangements and evaluate treatment outcomes with crizotinib therapy.

Methods: Patients with stage IV NSCLC adenocarcinoma histology were considered for this study. The study was conducted according to the ethical principles stated in the latest version of the Declaration of Helsinki and the applicable guidelines for good clinical practice. Clinical characteristics and treatment details were collected from patients' medical records.

Results: A total of 709 stage IV NSCLC adenocarcinoma patients were included in the study. There were 457 (64.46%) men and 252 (35.54%) women, with a median age of 60 years. *ROS1*-gene rearrangement was positive in 20 (2.82%) cases, 13 using Fluorescent In-Situ Hybridization (FISH), and two and five cases, respectively, using immunohistochemistry (IHC) and next-generation sequencing (NGS), followed by confirmation with FISH. Fourteen of the 20 patients with *ROS1*-gene rearrangement received crizotinib therapy, with an objective response rate of 64.28%. At a median follow-up of 6 months, the study had not achieved the end points of median progression free survival and overall survival.

Conclusion: *ROS1*-gene rearrangement was present at a relatively higher frequency of 2.8% in north Indian patients with lung adenocarcinoma and was successfully targeted by crizotinib therapy. Although the only US Food and Drug Administration and Conformité Européenne approved method for testing *ROS1* rearrangement is NGS, FISH alone or IHC with D4D6 antibody as initial screen with subsequent confirmation of IHC-positive cases by FISH are cost-effective methods in institutions lacking NGS facilities.

Keywords: NSCLC, *ROS1*, crizotinib

Introduction

With an overall 5-year survival rate of just 15%, lung cancer is the leading cause of cancer-related mortality across the globe.¹ According to a GLOBOCAN 2018 report, lung cancer was the largest contributor to new cases (2.09 million) and cancer-related deaths (1.76 million) among all cancers.² More than 70% of lung carcinomas are detected in the advanced stage. The molecular characterization of advanced non-small-cell lung cancer (NSCLC) followed by treatment with a corresponding inhibitor has become a well-established treatment strategy. The

Correspondence: Anurag Mehta
Laboratory Services, Rajiv Gandhi
Cancer Institute and Research Centre,
Sector V, Rohini, New Delhi 110085
Tel +91 9868 020 371
Email anumehta1@gmail.com

benefit in progression-free survival (PFS) and better quality of life through genome-directed therapy has raised the notion of “give the maximum number of patients a chance at genetic alteration-directed therapy”. It has been asserted that 64% of NSCLC patients harbour at least one activated pathway, with approximately two-thirds of these are actionable using available approved or off-label targeted therapies.^{3–5} The frequency of individual driver mutations, however, is population-specific. KRAS is the commonest driver in the Western population, but EGFR takes this place in Asian populations. *ALK*-fusion rearrangement, on the other hand, has more uniform distribution.^{5–8} *ROS1*-fusion rearrangement, the third actionable genetic change, despite occurring far less commonly, has evoked considerable interest, due to excellent objective response rates (ORRs; 72%) and substantial PFS of 19.3 months to *ALK* tyrosine-kinase inhibitors.^{9–12} Such gratifying results in *ROS1*-rearranged NSCLC necessitate a closer look at its incidence and response to a first-generation *ALK* tyrosine-kinase inhibitor (crizotinib) in different populations. The frequency of *ROS1* rearrangement has been reported in Western literature to be around 1%. However, *ROS1* incidence has not been widely reported from the Indian subcontinent.

Registration trials for *ROS1*-fusion rearrangement detection utilized fluorescence in situ hybridization (FISH), which is considered the gold standard. However, no testing methodology, assay system, or assay platform was given US Food and Drug Administration (FDA) approval till recently, when Oncomine Target Dx, a next-generation sequencing (NGS)-based multigene panel was accorded approval for EGFR-sensitizing mutations, *BRAF*^{V600E} mutations, and *ROS1*-fusion rearrangement.^{13–15} College of American Pathologists–International Association for the Study of Lung Cancer–Association for Molecular Pathology guidelines recognize immunohistochemistry (IHC) as a cost-effective screening tool, to be followed by FISH confirmation in positive cases. IHC with ROS1 (D4D6) rabbit monoclonal antibody (Cell Signaling Technology, Cambridge, UK) stained with Ventana benchmark XT immunostainer has sensitivity of 100% and specificity of 92%.^{16–18} However, the inadmissibly high false positivity rates necessitate FISH or NGS confirmation. We undertook this molecular epidemiological study to estimate the prevalence of *ROS1* rearrangements and evaluate treatment outcomes with crizotinib therapy in Indian lung adenocarcinoma patients.

Methods

Patients with stage IV NSCLC adenocarcinoma histology for the period May 2012 to June 2019 were considered for this study. Permission was obtained from the Institutional Review Board of Rajiv Gandhi Cancer Institute and Research Centre. The informed-consent requirement was waived, as the research was conducted on anonymized patient samples/data. The study was conducted according to the ethical principles stated in the latest version of the Declaration of Helsinki and applicable guidelines for good clinical practice. Clinical characteristics and treatment details were collected from patients' medical records.

FISH alone was performed on 498 cases. FISH was assayed on 4µm formalin-fixed, paraffin-embedded tumor tissue using a dual-color break-apart probe (ZytoLight Spec ROS1; ZytoVision, Germany), according to the manufacturer's instructions.^{15,17} The ZytoLight Spec ROS1 has been designed to detect translocations involving chromosomal region 6q22.1 harboring *ROS1*. It contains two directly labeled probes hybridizing to the 6q22.1 band. While the orange-fluorochrome directly labeled probe hybridizes distally, the green-fluorochrome directly labeled probe hybridizes proximally to the *ROS1*-breakpoint region of 6q22.1. FISH signal evaluation was performed using fluorescent microscopy (Leica DM6000 B) equipped with three filters (DAPI, green, red). FISH results were based on a minimum of 50 evaluable tumor cells. Fused, split, or isolated green/orange signals were detected and enumerated (Figure 1). The rearrangement-positive cell rate was defined as $([\text{number of cells with a split pattern} + \text{number of cells with isolated 3'} \{ \text{green} \}] \text{ pattern} / \text{total number of cells evaluated}) \times 100$.




Figure 1 ROS1 fluorescence in situ hybridization.

A cutoff of at least 15% break-apart and/or isolated green events was used as the threshold for *ROS1* FISH positivity. The *ROS1* tyrosine-kinase domain is encoded by the 3' part of the gene. The unpaired 3' signal indicates the relevant oncogenic fusion gene, whereas the unpaired 5' signal represents a likely nonfunctional reciprocal fusion product. As such, isolated 5' signals were not included in the total count.

Formalin-fixed, paraffin-embedded section of 4 µm thickness following fixation for 6–48 hours in neutral buffered formalin and conventional tissue processing were stained by IHC for ROS1 protein expression using rabbit monoclonal antibody to ROS1 clone D4D6 (Cell Signaling Technology) on a Ventana benchmark XT immunostainer (Ventana Medical Systems, Tuscon, AZ, USA). Slides were pretreated with EDTA buffer (pH 8.3) for 48 minutes and incubated with the primary mAb at a dilution of 1:100 for 40 minutes at 37°C. Detection was performed using an OptiView DAB IHC detection kit (Ventana Medical Systems). Moderate–strong granular cytoplasmic staining was considered positive, and these cases proceeded to confirmation by FISH using the aforementioned method. In sum, 111 cases were tested using IHC as screening method.

NGS was performed using an Ion AmpliSeq RNA-fusion lung cancer research panel (Thermo Fisher Scientific), which targets 70 fusion transcripts specific for lung cancer belonging to *ALK*, *RET*, *ROS1*, and *NTRK1* genes. A total of 100 cases were tested by NGS. All positive cases were orthogonally validated using FISH as a reference method. Statistical analysis was performed using Pearson's χ^2 or Fisher's exact test, whichever was appropriate for categorical variables. Logistic regression was performed to compare the study groups. Two-sided $p < 0.05$ was considered significant. Binary logistic regression with single independent variables was performed, and thus statistical correction was not applied to the p -values. Statistical analysis was performed using SAS version 9.4.

Results

A total of 709 stage IV NSCLC adenocarcinoma patients were included in the study. There were 457 (64.46%) men and 252 (35.54%) women, with a median age of 60 years. Of the 709 patients, 228 (32.16%) were smokers and 78 (11%) never-smokers. Baseline patient characteristics are presented in Table 1. Of the 709 cases, 498 were tested using FISH, whereas 111 and 100 each were tested using IHC or NGS, due either to the physician's choice of test or restricted availability of tissue. Result of molecular testing are shown in Table 2. *ROS1*-gene rearrangement was positive in 20

Table 1 Summary of Patient Demographics and Tumour Characteristics (N=709)

Median age, years (range)	60 (26–88)
Sex, n (%)	
Male	457 (64.46)
Female	252 (35.54)
Smoking, n (%)	
Smokers	228 (32.36)
Never-smokers	78 (11)
Unknown	403 (56.84)
Performance status	
1	293 (41.33)
2	83 (11.71)
3	27 (3.81)
4	22 (3.10)
Unknown	284 (40.05)
Grade, n (%)	
Well differentiated	79 (11.14)
Moderately differentiated	355 (50.07)
Poorly differentiated	275 (38.78)
Morphology, n (%)	
Papillary	13 (1.83)
Lepidic	9 (1.27)
Solid	68 (9.59)
Acinar	62 (8.74)
Acinar, solid	15 (2.12)
Acinar, papillary	17 (2.40)
Acinar, lepidic	17 (2.40)
Acinar, solid, lepidic	4 (0.56)
Acinar, papillary, lepidic	2 (0.28)
Acinar, papillary, solid	1 (0.14)
Papillary, lepidic	2 (0.28)
Papillary, solid	3 (0.42)
Not reported	496 (69.96)

Table 2 Results of Molecular Testing

	N=709 (%)
<i>ROS1</i>-gene rearrangement	
Positive	20 (2.82)
Wild type	689 (97.18)

(2.82%) cases. Thirteen of 20 positive cases of *ROS1*-gene arrangements were identified using FISH as the first definitive test. Two cases were recognized through IHC screening followed by confirmatory FISH and five cases by NGS with subsequent validation by FISH. The association of each individual factor with regard to *ROS1*-gene rearrangement is shown in Table 3. *ROS1*-gene rearrangement showed

Table 3 Association of Each Factor Vis-à-Vis *ROS1*-Gene Rearrangement

SI Number	Variable	χ^2	p-value
1	Sex	3.41	0.1813
2	Age	82.27	0.0298*
3	Cigarette smoking	20.54	0.0001*
4	Tobacco chewing	1.17	0.2796
5	Alcohol intake	3.69	0.1584
6	Histology	8.27	0.0820
7	Performance status	4.88	0.4312
8	Immunohistochemistry	41.61	0.0269*
9	Morphology	26.86	0.0201*

Note: *Significant.

Table 4 Distribution of *ROS1*-Gene Rearrangement

	ROS1-Gene Rearrangement		
	Wild-Type (%)	Mutated, n (%)	p-value
Sex			
Female	241 (33.99)	11 (1.55)	0.1813
Male	448 (63.19)	9 (1.37)	
Age, years			
20–40	41 (6.63)	4 (0.56)	0.0343*
40–60	328 (46.26)	11 (1.55)	
> 60	314 (44.29)	5 (0.71)	
Smoking history			
Never-smokers	70 (9.87)	8 (1.13)	0.0001*
Smoker	227 (32.02)	1 (0.14)	
Unknown	392 (55.29)	11 (1.55)	
Performance status			
1	281 (65.13)	12 (2.78)	0.4312
2	80 (18.56)	3 (0.70)	
3	27 (6.26)	0	
4	22 (5.10)	0	

Note: *Significant.

significant associations with age, cigarette smoking, IHC, and morphology ($p < 0.05$). Table 4 presents the distribution of *ROS1*-gene rearrangement across the study population. Smoking density could not be calculated, as patients were reticent in fully disclosing their smoking history.

Fourteen of the 20 patients with *ROS1*-gene rearrangement received crizotinib therapy, whereas six patients could not afford the therapy due to financial constraint. Of the 14 patients who received crizotinib therapy, only five patients received it as first-line therapy and nine as second-line therapy. Among those who received crizotinib therapy, nine (64.28%) achieved partial response, three (21.43%) stable

disease, and two (14.28%) progressive disease. There were four deaths, two each in patients who achieved partial response and progressive disease. Duration of response was 1.5 to 14 months. At a median follow-up of 6 months, the study had not achieved the endpoints of median PFS (Figure 2) and overall survival (OS; Figure 3). Estimated 1-year PFS and OS were 56.2% and 36.9%, respectively.

Discussion

The use of molecular profiling-based targeted therapies has significantly improved median PFS outcomes in NSCLC. The excellent response rate of crizotinib in *ROS1*-rearranged NSCLC has gained significant attention in the recent past. Here, we report the frequency of *ROS1* rearrangement and treatment outcomes in an Indian population. We found a 2.82% incidence of *ROS1*-gene rearrangement among 709




Figure 2 Progression-free survival with crizotinib therapy.




Figure 3 Overall survival with crizotinib therapy.

stage IV NSCLC adenocarcinoma patients. Two previous studies from India have reported the prevalence of *ROS1* rearrangements to be 2.9%¹⁹ and 4.1%²⁰ using FISH. The prevalence of *ROS1* rearrangements in Asian NSCLC populations has been reported to be 1.54%–2.59%.^{16,21,22} Similar prevalence of 1.7%–2.5% has been reported for Caucasian NSCLC populations.^{13,23} The prevalence (2.82%) of *ROS1*-gene rearrangement in our study is consistent with previously published reports for Indian, Asian, and Caucasian populations, with the exception of one study from India that reported much higher prevalence of 4.1%.²⁰

In the present study, a higher *ROS1* gene-rearrangement rate was observed in females than males (1.55% vs 1.27%), but the results were not statistically significant. In contrast to this observation, a previous study from India had all three female patients as higher,¹⁹ whereas another reported dominance for males (13 of 22).²⁰ We observed a positive correlation of *ROS1*-gene rearrangement in the never-smoker group compared to smokers (1.13% vs 0.14%, $p=0.0001$). Although all age-groups were affected, there was a positive correlation for the age-group 40–60 years (1.55%, $p=0.0343$). There was no specific association with morphology type (papillary, acinar lepidic, solid), and thus it cannot be used as a selection criterion for testing. Previously published studies for Asian and Caucasian populations also reported a higher rate of *ROS1*-gene rearrangement in younger, never-smoker, female patients and adenocarcinoma histology.^{22,24–26}

Although oncogenic drivers in NSCLC such as *EGFR*, *ALK*, and *ROS1* rearrangements, are mutually exclusive, there have been few reports on concomitant existence of *EGFR-ALK*,^{27–29} *EGFR-ROS1*,¹⁶ and *ALK-ROS1* mutations.¹³ Two cases in the present study also had concurrent *EGFR* mutation with *ROS1*-gene rearrangement. IHC serves as a rapid and cost-effective alternative to FISH, especially in low-resource settings. Although *ROS1* IHC readouts may lead to false-positive results, due to aneuploidy, two cases in our study were recognized through IHC screening, and both were found to be *ROS1*-positive on subsequent confirmation by FISH.

The PROFILE 1001 study found a very high ORR of 72% with crizotinib therapy among 50 patients with *ROS1*-rearranged NSCLC.³⁰ The study also demonstrated a very high disease-control rate of 90% and median PFS of 19.2 months, leading to the FDA approval of crizotinib for the treatment of advanced *ROS1*-rearranged NSCLC. Updated results of PROFILE 1001 showed similar ORR and median PFS among 53 patients.³¹ Three subsequent studies of

crizotinib in *ROS1*-rearranged NSCLC showed shorter median PFS of 9–13.4 months.^{32–34} Updated results of the AcSé phase II trial showed a higher best ORR of 69.4% during treatment in 37 patients of an *ROS1*-translocation cohort.³⁵ Similarly, the METROS phase II trial also showed a very high ORR of 65% and median PFS of 22.8 (95% CI 15.2–30.3 months with crizotinib therapy among 26 patients with *ROS1*-rearranged pretreated NSCLC.³⁶ Two studies from India have reported a good response to crizotinib therapy.^{19,20} In one study, crizotinib therapy achieved an ORR of 93.8%, with 1- and 2-year OS of 72% and 54%, respectively.²⁰ A third study from India also showed a good response rate of 80% with crizotinib therapy in *ROS1*-rearranged NSCLC patients.³⁷ At a median follow-up of 9 months, median PFS and OS had not been reached. In our study, 14 (70%) of the 20 patients with *ROS1*-gene rearrangement received crizotinib therapy. With an ORR of 64.28% and clinical benefit rate of 85.71%, the results of our study show much lower ORR than previously published reports. At a median follow-up of 6 months, the study had not achieved the end points of median PFS and OS, and the same shall be presented in future publications.

There were four (28.57%) deaths in our study, two each in patients with partial response and progressive disease, and no grade 3/4 toxicities. Updated results of PROFILE 1001³¹ showed progressive disease/deaths in 26 (49%) patients, with no grade 3/4 treatment-related adverse events. Similarly, two studies from India showed progressive disease on first assessment in one (6.25%)²⁰ and two (66.66%)¹⁹ patients, along with no grade 3/4 treatment-related adverse events. More recently, entrectinib has shown clinical activity in patients with locally advanced or metastatic *ROS1* fusion-positive NSCLC. Entrectinib is an *ROS1* inhibitor that has been designed to penetrate effectively and remain in the central nervous system. In an integrated analysis of three phase I–II trials, 41 (77%) of 53 locally advanced or metastatic *ROS1* fusion-positive NSCLC patients had objective response with entrectinib at a dose of at least 600 mg orally once per day. Median duration of response was 24.6 months with a manageable safety profile. However, these findings need confirmation in randomized controlled clinical trials with a much larger patient population.³⁸

Conclusion

Our study reports data on *ROS1*-gene rearrangement for Indian patients with lung adenocarcinoma using IHC, NGS, and FISH techniques. The incidence of *ROS1*-gene

rearrangement (2.82%) in this Indian population was consistent to that previously reported and supports the clinical utility of crizotinib therapy in this patient subgroup. The inclusion of IHC for initial screening of *ROS1*-gene rearrangement followed by confirmation using FISH seems justified in low-resource settings.

Disclosure

The authors report no conflicts of interest in this work. No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

References

- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. *CA Cancer J Clin*. 2008;58:71–96. doi:10.3322/CA.2007.0010
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394–424. doi:10.3322/caac.v68.6
- Tsao AS, Papadimitrakopoulou VA. The future of NSCLC: molecular profiles guiding treatment decisions. *Oncology*. 2011;25:1–3.
- Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. *Ann Oncol*. 2011;22:2616–2624. doi:10.1093/annonc/mdr489
- Kris MG, Johnson BE, Kwiatkowski DJ. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC). *J Clin Oncol*. 2011;29:Abstr CRA7506. doi:10.1200/jco.2011.29.15_suppl.cra7506
- Okamoto I, Mitsudomi T, Nakagawa K, Fukuoka M. The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutation. *Ther Adv Med Oncol*. 2010;2:301–307. doi:10.1177/1758834010370698
- Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. *Nature*. 2007;448:561–566. doi:10.1038/nature05945
- Zhang X, Zhang S, Yang X, et al. Fusion of EML4 and ALK associated with development of lung adenocarcinomas lacking EGFR and K-RAS mutations is correlated with ALK expression. *Mol Cancer*. 2010;9:188. doi:10.1186/1476-4598-9-188
- Moro-Sibilot D, Cozic N, Pérol M, et al. OA12.03 activity of crizotinib in MET or ROS1 positive (+) NSCLC: results of the AcSe trial. *J Thorac Oncol*. 2018;13(10):S348. doi:10.1016/j.jtho.2018.08.301
- Solomon BJ, Kim DW, Wu YL, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer. *J Clin Oncol*. 2018;36(22):2251–2258. doi:10.1200/JCO.2017.77.4794
- Lim SM, Kim HR, Lee JS, et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. *J Clin Oncol*. 2017;35(23):2613–2618. doi:10.1200/JCO.2016.71.3701
- Doebele R, Ahn M, Siena S, et al. OA02.01 efficacy and safety of entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC). *J Thorac Oncol*. 2018;13(10):S321–S322. doi:10.1016/j.jtho.2018.08.239
- Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. *J Clin Oncol*. 2012;30:863–870. doi:10.1200/JCO.2011.35.6345
- Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. *Nat Med*. 2012;18:378–381. doi:10.1038/nm.2658
- Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. *Clin Cancer Res*. 2012;18:4570–4579. doi:10.1158/1078-0432.CCR-12-0550
- Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. *Clin Cancer Res*. 2012;18:4449–4457. doi:10.1158/1078-0432.CCR-11-3351
- Bubendorf L, Büttner R, Al-Dayel F, et al. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. *Virchows Arch*. 2016;469:489–503. doi:10.1007/s00428-016-2000-3
- Sholl LM, Sun H, Butaney M, et al. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. *Am J Surg Pathol*. 2013;37:1441–1449. doi:10.1097/PAS.0b013e3182960fa7
- Suryavanshi M, Panigrahi MK, Kumar D, et al. ROS1 rearrangement and response to crizotinib in stage IV non-small cell lung cancer. *Lung India*. 2017;34(5):411–414. doi:10.4103/lungindia.lungindia_116_17
- Joshi A, Pande N, Noronha V, et al. ROS1 mutation non-small cell lung cancer-access to optimal treatment and outcomes. *Ecancermedicalscience*. 2019;13:900. doi:10.3332/ecancer.2019.900
- Zeng L, Li Y, Xiao L, et al. Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer. *Onco Targets Ther*. 2018;11:6937–6945. doi:10.2147/OTT
- Zhang Q, Wu C, Ding W, et al. Prevalence of ROS1 fusion in Chinese patients with non-small cell lung cancer. *Thorac Cancer*. 2019;10(1):47–53. doi:10.1111/tca.2019.10.issue-1
- Wiesweg M, Eberhardt WEE, Reis H, et al. High prevalence of concomitant oncogene mutations in prospectively identified patients with ROS1-positive metastatic lung cancer. *J Thorac Oncol*. 2017;12(1):54–64. doi:10.1016/j.jtho.2016.08.137
- Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. *Nature*. 2014;511:543–550. doi:10.1038/nature13385
- Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat Med*. 2017;23:703–713. doi:10.1038/nm.4333
- Chen YF, Hsieh MS, Wu SG, et al. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. *J Thorac Oncol*. 2014;9:1171–1179. doi:10.1097/JTO.0000000000000232
- Tanaka H, Hayashi A, Morimoto T, et al. A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene. *BMC Cancer*. 2012;12:558. doi:10.1186/1471-2407-12-558
- Lee JK, Kim TM, Koh Y, et al. Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. *Lung Cancer*. 2012;77(2):460–463. doi:10.1016/j.lungcan.2012.04.012
- Popat S, Vieira de Araújo A, Min T, et al. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. *J Thorac Oncol*. 2011;6(11):1962–1963. doi:10.1097/JTO.0b013e31822e5e5e
- Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med*. 2014;371:1963–1971. doi:10.1056/NEJMoa1406766
- Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. *Ann Oncol*. 2019;30(7):1121–1126. doi:10.1093/annonc/mdz131
- Moro-Sibilot D, Faivre L, Zalcman G, et al. Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial. *J Clin Oncol*. 2015;33(suppl):abstr 8065. doi:10.1200/jco.2015.33.15_suppl.8065

33. Mazières J, Zalcman G, Crinò L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. *J Clin Oncol*. 2015;33:992–999. doi:10.1200/JCO.2014.58.3302
34. Goto K, Yang JC, Kim DW, et al. Phase II study of crizotinib in East Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC). *J Clin Oncol*. 2016;34(suppl):abstr 9022. doi:10.1200/JCO.2016.34.15_suppl.9022
35. Moro-Sibilot D, Cozic N, Pérol M, et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. *Ann Oncol*. 2019;30:1985–1991. doi:10.1093/annonc/mdz407
36. Landi L, Chiari R, Tiseo M, et al. Crizotinib in MET-deregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS): a Phase II, prospective, multicenter, two-arms trial. *Clin Cancer Res*. 2019;25(24):7312–7319. doi:10.1158/1078-0432.CCR-19-0994
37. Noronha V, Chandrakanth MV, Joshi AP, et al. ROS1 rearranged nonsmall cell lung cancer and crizotinib: an Indian experience. *Indian J Cancer*. 2017;54(2):436–438. doi:10.4103/ijc.IJC_269_17
38. Drilon A, Siena S, Dziadziuszko R, et al. trial investigators. entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. *Lancet Oncol*. 2019.

Lung Cancer: Targets and Therapy

Dovepress

Publish your work in this journal

Lung Cancer: Targets and Therapy is an international, peer-reviewed, open access journal focusing on lung cancer research, identification of therapeutic targets and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient. Specific topics covered in the journal include: Epidemiology,

detection and screening; Cellular research and biomarkers; Identification of biotargets and agents with novel mechanisms of action; Optimal clinical use of existing anticancer agents, including combination therapies; Radiation and surgery; Palliative care; Patient adherence, quality of life, satisfaction; Health economic evaluations.

Submit your manuscript here: <http://www.dovepress.com/lung-cancer-targets-therapy-journal>